A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

Morris D. Groves; Vinay K. Puduvalli; Susan M. Chang; Charles A. Conrad; Mark R. Gilbert; Ivo W. Tremont-Lukats; Ta-Jen Liu; Pamela Peterson; David Schiff; Timothy F. Cloughesy; Patrick Y. Wen; Harry Greenberg; Lauren E. Abrey; Lisa M. DeAngelis; Kenneth R. Hess; Kathleen R. Lamborn; Michael D. Prados; W. K. Alfred Yung

首页> 外文期刊>Journal of Neuro-Oncology >A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

【24h】

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

机译：替莫唑胺+沙利度胺治疗复发性多形性胶质母细胞瘤的北美脑肿瘤联盟（NABTC 99-04）II期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).

机译：实验室和临床数据表明，如果将抗血管生成剂沙利度胺与细胞毒性剂联合使用，可能对复发性多形性胶质母细胞瘤（GBM）有效。

著录项

来源
《Journal of Neuro-Oncology 》 |2007年第3期| 271-277| 共7页
作者
Morris D. Groves; Vinay K. Puduvalli; Susan M. Chang; Charles A. Conrad; Mark R. Gilbert; Ivo W. Tremont-Lukats; Ta-Jen Liu; Pamela Peterson; David Schiff; Timothy F. Cloughesy; Patrick Y. Wen; Harry Greenberg; Lauren E. Abrey; Lisa M. DeAngelis; Kenneth R. Hess; Kathleen R. Lamborn; Michael D. Prados; W. K. Alfred Yung;
展开▼
作者单位

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

The University of California San Francisco CA USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

The University of Pittsburg Medical Center Pittsburg PA USA;

University of California Los Angeles CA USA;

Dana Farber/Brigham and Women‘s Cancer Center Boston MA USA;

University of Michigan Ann Arbor MI USA;

Memorial Sloan-Kettering Cancer Center New York NY USA;

Memorial Sloan-Kettering Cancer Center New York NY USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

The University of California San Francisco CA USA;

The University of California San Francisco CA USA;

Department of Neuro-Oncology The University of Texas MD Anderson Cancer Center 1400 Holcombe 431 Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Glioblastoma multiforme; Clinical trial; Controlled; Temozolomide; Thalidomide; Angiogenesis inhibitors; Vascular endothelial growth factor; Basic fibroblast growth factor; Interleukin 8;

机译：多形性胶质母细胞瘤;临床试验;对照;替莫唑胺;沙利度胺;血管生成抑制剂;血管内皮生长因子;基础成纤维细胞生长因子;白介素8;

相似文献

外文文献
中文文献
专利

1. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. [J] . Groves MD, Puduvalli VK, Chang SM, Journal of neuro-oncology. . 2007 ,第3期

机译：替莫唑胺加沙利度胺用于复发性多形性胶质母细胞瘤的北美脑肿瘤联盟（NABTC 99-04）II期试验。
2. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). [J] . Butowski N, Chang SM, Junck L, Journal of neuro-oncology. . 2009 ,第2期

机译：聚-ICLC放射治疗新诊断的幕上胶质母细胞瘤成年患者的一项II期临床试验：北美脑肿瘤联合会（NABTC01-05）。
3. Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study. [J] . Jaeckle KA, Hess KR, Yung WK, Journal of Clinical Oncology . 2003 ,第12期

机译：替莫唑胺和13-顺-视黄酸治疗复发性和进行性恶性神经胶质瘤的II期评估：北美脑肿瘤联合研究。
4. Glioblastoma multiforme treated by the chemotherapeutic agent temozolomide in vivo: a 4D simulation model of the tumor response [C] . V.P. Antipas, G.S. Stamatakos, N.K. Uzunoglu . 2005

机译：替莫唑胺在体内治疗多形性胶质母细胞瘤：肿瘤反应的4D模拟模型
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study [O] . Michael D. Prados, W.K. Alfred Yung, Howard A. Fine, 2004

机译：BCNU和替莫唑胺用于复发性多形性胶质母细胞瘤的2期研究：北美脑肿瘤联合会研究
7. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study1 [O] . Prados, Michael D., Yung, W.K. Alfred, Fine, Howard A., 2004

机译：BCNU和替莫唑胺用于复发性多形性胶质母细胞瘤的2期研究：北美脑肿瘤联盟研究1

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

摘要

著录项

相似文献

相关主题

期刊订阅